Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours

British Journal of Haematology

Volumn 148, Issue 1, 2010, Pages 144-153

  Isotani, Mayu ^a   Yamada, Osamu ^a   Lachowicz, Joshua L ^b   Tamura, Kyoichi ^a   Yagihara, Hiroko ^a   Fujino, Yasuhito ^c   Ono, Kenichiro ^d   Washizu, Tsukimi ^a   Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b Redbank Veterinary Hospital   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cats; Kit fifth IgD; Mast cell tumours; Mutation; Tyrosine kinase inhibition

Indexed keywords

IMATINIB; IMMUNOGLOBULIN D; MESSENGER RNA; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAT; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; EXON; GENE MUTATION; MASTOCYTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; TREATMENT RESPONSE; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CAT DISEASES; CATS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG EVALUATION, PRECLINICAL; EXONS; IMMUNOGLOBULIN D; MASTOCYTOSIS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

EID: 72249097498     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07926.x     Document Type: Article

References (32)

1. Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, B.J. Metcalfe, D.D. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology, 31, 686 692.
2. Akin, C., Fumo, G., Yavuz, A.S., Lipsky, P.E., Neckers, L. Metcalfe, D.D. (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood, 103, 3222 3225.
3. Bonkobara, M., Zukas, P.K., Shikano, S., Nakamura, S., Cruz, P.D. Ariizumi, K. (2001) Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. Journal of Immunology, 167, 6893 6900.
4. Büttner, C., Henz, B.M., Welker, P., Sepp, N.T. Grabbe, J. (1998) Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. Journal of Investigative Dermatology, 111, 1227 1231.
5. Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Löwenberg, B. Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 775 777.
6. Dank, G., Chien, M.B. London, C.A. (2002) Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats. American Journal of Veterinary Research, 63, 1129 1133.
7. Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., Fletcher, J.A., Silverman, S.G., Silberman, S.L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B.J., Corless, C., Fletcher, C.D. Joensuu, H. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine, 347, 472 480.
8. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408 2417. (Pubitemid 44903745)
9. Frost, M.J., Ferrao, P.T., Hughes, T.P. Ashman, L.K. (2002) Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Molecular Cancer Therapeutics, 1, 1115 1124.
10. Garcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., Aldanondo, I., Sanchez, L., Dominguez, M., Botana, L.M., Sanchez-Jimenez, F., Sotlar, K., Almeida, J., Escribano, L. Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, 2366 2372.
11. Hartmann, K., Wardelmann, E., Ma, Y., Merkelbach-Bruse, S., Preussner, L.M., Woolery, C., Baldus, S.E., Heinicke, T., Thiele, J., Buettner, R. Longley, B.J. (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology, 129, 1042 1046.
12. Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Silberman, S., Dimitrijevic, S. Fletcher, J.A. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology, 21, 4342 4349.
13. Heinrich, M.C., Joensuu, H., Demetri, G.D., Corless, C.L., Apperley, J., Fletcher, J.A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S.G., Seymour, J., Di Scala, L., van Oosterom, A., Herrmann, R., Nikolova, Z. McArthur, A.G. (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clinical Cancer Research, 14, 2717 2725.
14. Hoffmann, K.M., Moser, A., Lohse, P., Winkler, A., Binder, B., Sovinz, P., Lackner, H., Schwinger, W., Benesch, M. Urban, C. (2008) Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood, 112, 1655 1657.
15. Isotani, M., Tamura, K., Yagihara, H., Hikosaka, M., Ono, K., Washizu, T. Bonkobara, M. (2006) Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Veterinary Immunology and Immunopathology, 114, 168 172.
16. Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., Kato, R., Kobayashi, T., Fujita, M., Fujino, Y., Setoguchi, A., Ono, K., Washizu, T. Bonkobara, M. (2008) Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine, 22, 985 988.
17. Lanternier, F., Cohen-Akenine, A., Palmerini, F., Feger, F., Yang, Y., Zermati, Y., Barète, S., Sans, B., Baude, C., Ghez, D., Suarez, F., Delarue, R., Casassus, P., Bodemer, C., Catteau, A., Soppelsa, F., Hanssens, K., Arock, M., Sobol, H., Fraitag, S., Canioni, D., Moussy, A., Launay, J.M., Dubreuil, P., Hermine, O. Lortholary, O. (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE, 3, e1906.
18. Letard, S., Yang, Y., Hanssens, K., Palmérini, F., Leventhal, P.S., Guéry, S., Moussy, A., Kinet, J.P., Hermine, O. Dubreuil, P. (2008) Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Molecular Cancer Research, 6, 1137 1145.
19. Litster, A.L. Sorenmo, K.U. (2006) Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. Journal of Feline Medicine and Surgery, 8, 177 183.
20. Longley, B.J., Metcalfe, D.D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.Z., Heitjan, D. Ma, Y. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the United States of America, 96, 1609 1614.
21. Longley, B.J., Reguera, M.J. Ma, Y. (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research, 25, 571 576.
22. Miller, M.A., Nelson, S.L., Turk, J.R., Pace, L.W., Brown, T.P., Shaw, D.P., Fischer, J.R. Gosser, H.S. (1991) Cutaneous neoplasia in 340 cats. Veterinary Pathology, 28, 389 395.
23. Orfao, A., Garcia-Montero, A.C., Sanchez, L. Escribano, L. (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. British Journal of Haematology, 138, 12 30.
24. Pardanani, A., Elliott, M., Reeder, T., Li, C.Y., Baxter, E.J., Cross, N.C. Tefferi, A. (2003) Imatinib for systemic mast-cell disease. Lancet, 362, 535 536.
25. Roskoski, R. (2005) Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochemical and Biophysical Research Communications, 338, 1307 1315.
26. Spangler, W.L. Culbertson, M.R. (1992) Prevalence and type of splenic diseases in cats: 455 cases (1985-1991). Journal of the American Veterinary Medical Association, 201, 773 776.
27. Vega-Ruiz, A., Cortes, J.E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H.M. Verstovsek, S. (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research, 33, 1481 1484.
28. Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondo, F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., Rege-Cambrin, G., Elia, L., Bertieri, R., Annino, L., Foà, R., Baccarani, M. Mandelli, F. (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood, 109, 3676 3678.
29. Wilcock, B.P., Yager, J.A. Zink, M.C. (1986) The morphology and behavior of feline cutaneous mastocytomas. Veterinary Pathology, 23, 320 324.
30. Yarden, Y. Ullrich, A. (1988) Growth factor receptor tyrosine kinases. Annual Review of Biochemistry, 57, 443 478.
31. Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I. Schlessinger, J. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell, 130, 323 334.
32. Zhang, L.Y., Smith, M.L., Schultheis, B., Fitzgibbon, J., Lister, T.A., Melo, J.V., Cross, N.C. Cavenagh, J.D. (2006) A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leukemia Research, 30, 373 378.